Elisabeth Bloemena
Overview
Explore the profile of Elisabeth Bloemena including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
132
Citations
2661
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Muijlwijk T, Nauta I, van der Lee A, Grunewald K, Brink A, Ganzevles S, et al.
Nat Commun
. 2025 Feb;
16(1):1705.
PMID: 39962066
No abstract available.
2.
Nauta I, Nijenhuis D, Ganzevles S, Raaff P, Kloosterman J, Bloemena E, et al.
Cancers (Basel)
. 2025 Jan;
17(1.
PMID: 39796740
Background/objectives: Most studies on the interaction between the immune system and cancer focus on T-cells, whereas studies on tumor-infiltrating B-lymphocytes (TIL-Bs) are still underrepresented. The aim of this study was...
3.
Muijlwijk T, Nauta I, van der Lee A, Grunewald K, Brink A, Ganzevles S, et al.
Nat Commun
. 2024 Oct;
15(1):9060.
PMID: 39428388
Cancer is caused by an accumulation of somatic mutations and copy number alterations (CNAs). Besides mutations, these copy number changes are key characteristics of cancer development. Nonetheless, some tumors show...
4.
Muijlwijk T, Nijenhuis D, Ganzevles S, Ekhlas F, Ballesteros-Merino C, Peferoen L, et al.
J Immunother Cancer
. 2024 Jul;
12(7).
PMID: 39053947
Background: Approximately 50% of head and neck squamous cell carcinomas (HNSCC) recur after treatment with curative intent. Immune checkpoint inhibitors are treatment options for recurrent/metastatic HNSCC; however, less than 20%...
5.
Wondergem N, Miedema I, van de Ven R, Zwezerijnen G, de Graaf P, Karagozoglu K, et al.
J Immunother Cancer
. 2024 Jul;
12(7).
PMID: 39038919
Background: Addition of neoadjuvant immune checkpoint inhibition to standard-of-care interventions for locally advanced oral cancer could improve clinical outcome. Methods: In this study, 16 evaluable patients with stage III/IV oral...
6.
Nauta I, Peferoen L, Brakenhoff R, Leemans C, Bloemena E
J Oral Pathol Med
. 2024 Jun;
53(8):544-550.
PMID: 38945694
Background: A major challenge in the clinical management of oral cavity squamous cell carcinoma is local relapse. Even when surgical margins are tumor-free, local relapses occur frequently, and relapse prediction...
7.
de Vries T, Schoenmaker T, Peferoen L, Krom B, Bloemena E
Front Oral Health
. 2024 May;
5:1386904.
PMID: 38783986
Curricular reform provides new opportunities to renovate important pillars of the dentistry curriculum, such as immunology and pathology, with novel approaches that appeal to new generations of students. When redesigning...
8.
Wils L, Buijze M, Stigter-van Walsum M, Brink A, van Kempen B, Peferoen L, et al.
Cells
. 2024 Apr;
13(8.
PMID: 38667326
Precancerous cells in the oral cavity may appear as oral potentially malignant disorders, but they may also present as dysplasia without visual manifestation in tumor-adjacent tissue. As it is currently...
9.
Evren I, Najim A, Poell J, Brouns E, Wils L, Peferoen L, et al.
Oral Dis
. 2023 Nov;
30(5):2991-3003.
PMID: 37936517
Objectives: Evaluate whether regular follow-up of oral leukoplakia (OL) resulted in early detection of malignant transformation (MT). Method: Two hundred and twenty-two consecutive patients with OL (147 females, 75 males);...
10.
Bakema J, Stigter-van Walsum M, Harris J, Ganzevles S, Muthuswamy A, Houtkamp M, et al.
Mol Cancer Ther
. 2023 Oct;
23(2):187-198.
PMID: 37828725
Significance: This work shows preclinical in vitro and in vivo antitumor activity of the antibody-drug conjugate Tisotumab vedotin in head and neck cancer models, and enhanced activity in combination with...